摘要
丙型肝炎可发展为肝硬化或者肝细胞癌,给患者家庭和社会造成沉重的疾病负担。丙型肝炎是人类面临的重大公共威胁之一,消除丙型肝炎是人类共同的目标。直接抗病毒药物(DAA)治疗是目前较为安全可达到较高的治愈率的丙型肝炎治疗方案,可以靶向不同HCV基因型,使得HCV感染消除成为可能。我国积极推广DAA临床应用,加快药物审批,提高DAA可及性,加强人群干预。国家医疗保障局逐步将DAA纳入国家医保目录,为消除HCV感染提供了有力保障。为响应世界卫生组织提出的2030年消除病毒性肝炎作为公共卫生危害的目标,近年来我国相继发布国家策略规划及行动计划,在HCV感染消除工作中取得了较大的成就,形成全社会多部门联合防治,积极迈向消除HCV感染的目标。本文着眼于国内HCV感染的现状和防治工作进展突出的防治消除策略,分析总结HCV感染防治微消除的实践进程,为我国开展HCV感染消除工作提供政策参考,助力实现全面消除HCV感染的目标。
Hepatitis C virus(HCV)can develop into liver cirrhosis or hepatocellular carcinoma,imposing a heavy burden on the patient’s family and the society.Hepatitis C is one of the major public threats for humans,and eliminating hepatitis C is a common goal of all humans.Direct-acting antiviral agents(DAAs)are currently a relatively safe treatment regimen for hepatitis C that can reach a relatively high cure rate and can target different HCV genotypes,making it possible to eliminate HCV infection.China actively promotes the clinical application of DAAs,accelerates drug approval,improves the accessibility of DAAs,and strengthens population intervention.National Medical Insurance Administration has gradually included DAAs in the national medical insurance directory,providing strong support for eliminating HCV infection.In response to the WHO’s goal of eliminating viral hepatitis as a public health hazard by 2030,China has successively released national strategic plans and action plans in recent years,making significant achievements in HCV infection elimination,forming a joint prevention and control system across multiple sectors of the society,and ultimately achieving the goal of eliminating HCV infection.With a focus on the current status of HCV infection in China and prominent prevention and control strategies,this article analyzes and summarizes the practical process of the prevention,control,and micro-elimination of HCV infection,in order to provide a policy reference for carrying out HCV elimination in China and help to achieve the goal of comprehensive elimination of HCV infection.
作者
张海莹
饶慧瑛
陈红松
ZHANG Haiying;RAO Huiying;CHEN Hongsong(Peking University People’s Hospital,Peking University Hepatology Institute,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases,Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis,Beijing 100044,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2024年第4期649-653,共5页
Journal of Clinical Hepatology
关键词
丙型肝炎
感染
疾病消除
Hepatitis C
Infections
Disease Eradication
